Not all IP law is transferable
Thursday 15 July
Faraz Kermani, Scrip Analyst, says that the pharma sector is a case in point
The battle for supremacy between Europe and the US in the fields of pharmaceutical R&D and innovation has pointlessly flared up once again. A recently published survey by international intellectual property specialists Marks & Clerk indicates that the US IP system is viewed as being more favourable to innovation and that President Obama's recently passed healthcare reforms are proving to be increasingly palatable for big pharma.